Matching-adjusted indirect treatment comparison (MAIC) of teclistamab (tec) versus belantamab mafodotin (belamaf) for the treatment of patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM)

This article has no abstract
Epistemonikos ID: 45bbc4c947bba43764dd22979263f63b154a4d71
First added on: Feb 14, 2025